Topics

Competitor Landscape: Renal Anemia [Report Updated: 30112018] Prices from USD $5632

22:16 EST 2 Dec 2019 | BioPortfolio Reports

Competitor Landscape: Renal Anemia


Summary


Sociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current potential future product positioning, and forecast approval dates by quarter for candidates in Phase II development, or higher

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma's view of the disease landscape

Landscape Updates: Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product's lifecycle management initiatives; Market Entry' Direction of Travel' positioning analysis for pipeline currently approved therapies

Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drugspecific events milestones until YE 2019

Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drugspecific events milestones until YE 2019


Key Highlights


Roxadustat is still expected to be first HIFPHI to launch in the EU US markets, which may contribute to its superior uptake vs. other HIFPHI candidates, given the current lack of clinical differentiation between candidates of this class

In addition to progressing vadadustat's Phase III trials in Japan, Mitsubishi Tanabe also appears focused on understanding the impact of a commonly used renal anemia strategy, iron supplementation, on the pharmacokinetics of vadadustat

Daprodustat's Phase III data appears to strengthen the asset's longterm safety and efficacy profile, with daprodustat on track to become the second or third HIFPHI approved in Japan for DDCKD.


Scope


The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements press releases, earnings calls and clinical trial databases clinicaltrials.gov

Sociable Pharma applies disease drug specific assumptions in order to forecast US EU approvals for drugs in Phase II development, or higher these are outlined in the report Appendix

Forecasts are presented in pipeline forecast figures detailed tables

Market Entry' Direction of Travel' positioning analysis for pipeline currently approved therapies is also provided.


Reasons to buy


Provides details on forecast US EU approvals for pipeline drugs in Phase II development or higher

Includes potential positioning strategies that companies may adopt for their novel assets once they are approved launched in the market

Reviews ongoing lifecycle management strategies for existing players in the market

A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Original Article: Competitor Landscape: Renal Anemia [Report Updated: 30112018] Prices from USD $5632

NEXT ARTICLE

More From BioPortfolio on "Competitor Landscape: Renal Anemia [Report Updated: 30112018] Prices from USD $5632"

Quick Search

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...